Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
about
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerThe Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTargeting the PI3K signaling pathway in cancerPersonalized treatment for advanced colorectal cancer: KRAS and beyondIn vitro human cell line models to predict clinical response to anticancer drugsKRAS as a Therapeutic TargetDrosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate TherapeuticNovel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerPAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signalingUsing multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor bindingDiscovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorIdentifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discoveryAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KInhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinibBAYESIAN SPARSE GRAPHICAL MODELS FOR CLASSIFICATION WITH APPLICATION TO PROTEIN EXPRESSION DATA.Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEKImproved microarray-based decision support with graph encoded interactome dataStemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment.Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer.Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancerPI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cellsActivation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancerIdentification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell linesIdentification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysisGABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2).A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unitIdentification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.Breast cancer genomes--form and functionLapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.The evolution of the TOR pathway and its role in cancer.Treatment options for patients with triple-negative breast cancerBRAFV600E negatively regulates the AKT pathway in melanoma cell lines.K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
P2860
Q24338724-2004F1F1-FCDC-4091-9310-7D15D1915CF9Q24616946-12E16220-CACF-451F-B696-0DE2BB805510Q24647554-9DE2413A-45BA-429D-8CD3-95F644760F56Q26822817-80C4392C-88D6-4F01-A5BF-B0E5CFAF6019Q27000665-EFF77166-A461-44CA-969C-962C328F1BB3Q27007866-E3AB8C77-E54C-4557-BAE1-98D2B4AD0355Q27319935-A4442F99-19FC-4BE0-A2E1-DCB5D2C4B5E9Q27684146-DDD29B35-1F6B-4B7A-BEC7-3CA1D63034B7Q28076490-F4F63024-6A9F-4C37-A25D-CB0E7783E529Q28253621-716B2B66-929E-4853-8B45-2054AB1E7E01Q28478631-83C07083-87E7-4881-880C-317FFB372678Q28540161-BA3D5CF4-4095-496B-86C8-73DE6C9E9903Q28540918-FA4DCFBD-2A61-4132-A4BD-68A9065A36F1Q29614757-0795CC10-06D8-406F-99D8-B5A8228BE466Q30422319-6B9B5A2F-51AE-42AF-81A4-5C6D8FC78E8AQ30985471-C1BA59A8-E404-4BDE-9522-0CF71D213451Q33399049-7C616CB6-992E-4539-BB51-F7156D400CB0Q33562476-455C59BB-23D0-430F-8D2D-4464874A1CDAQ33564252-DE07D992-05D9-4BAB-BC5D-D02193FEDF2BQ33572252-359309EF-07E2-4466-BA50-DA1F0891E1E6Q33592917-5522D867-1FAF-465F-B595-3FFF4DEDB6D7Q33638654-DE581F68-F7B1-40A0-AF6E-BD54E8027E68Q33646519-FEFAE4B3-F74A-4D8D-88CD-7DDE52607C7CQ33687272-F0F7A0E8-9453-44BA-95DF-C93E90272151Q33714946-78C741CD-CAA7-4DF3-AF86-656D1AFAA362Q33829455-C2CE1ED5-5A5B-4F7D-93DB-6387CEF03687Q33875120-DE81D1CF-32A7-41F3-A542-A3B12FA99B92Q33945648-3303F24A-3A27-4C65-8F2C-B0A31202A751Q33956177-4B5813FD-F11B-4AE1-AD01-D1B8F2D2BD22Q34060031-83E51B7C-AC3C-438E-93F6-CFD5990F2399Q34101667-982785EE-F3C2-4E67-9A55-3C0A297FB3A2Q34107170-C1D24E4F-DBC5-4D29-81DC-2B0F926E8181Q34122784-771A713F-6FB0-4E82-B200-3F9C23AA3114Q34129528-1C90A416-906F-4268-8388-A0849869678CQ34207688-CC28EA4B-091E-4C8D-9BA1-A894474175F0Q34291564-063EEF07-6B1E-484D-B773-F7D3C3A28EB4Q34318188-33308E89-CAC8-45AB-8501-12B41A7C5998Q34331406-837E26B7-CD70-495F-ACAE-BD4EDAC10397Q34374407-0F046E15-B207-4FBE-9E3E-302AB20479AEQ34406302-1AC31A3B-9C2C-45A6-9E7B-5EBB1E971219
P2860
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Basal subtype and MAPK/ERK kin ...... ancer cells to MEK inhibition.
@en
Basal subtype and MAPK/ERK kinase
@nl
type
label
Basal subtype and MAPK/ERK kin ...... ancer cells to MEK inhibition.
@en
Basal subtype and MAPK/ERK kinase
@nl
prefLabel
Basal subtype and MAPK/ERK kin ...... ancer cells to MEK inhibition.
@en
Basal subtype and MAPK/ERK kinase
@nl
P2093
P2860
P1433
P1476
Basal subtype and MAPK/ERK kin ...... ancer cells to MEK inhibition.
@en
P2093
Andrew J Wyrobek
Debopriya Das
Doris Siwak
Frank McCormick
Gordon B Mills
Heidi S Feiler
Joe W Gray
Kevan M Shokat
Laura M Heiser
Mina J Bissell
P2860
P304
P356
10.1158/0008-5472.CAN-08-3389
P407
P577
2009-01-01T00:00:00Z